Insomnia Market Synopsis

U.S. Insomnia Market Size Was Valued at USD 4.42 Billion in 2022 and is Projected to Reach USD 6.68 Billion by 2030, Growing at a CAGR of 5.3 % From 2023-2030.

U.S. Insomnia is a sleep disorder that makes it difficult to fall asleep or stay asleep. A person may also wake up too early and not be able to get back to sleep.

  • Low stamina, daytime sleepiness, depression, and irritability are among the symptoms. It is a very common disorder that affects millions of people all over the world. Circadian rhythm disruption, chronic pain, hyperthyroidism, menopause, psychological stress, and other medical conditions all contribute to insomnia. Excessive use of drugs such as caffeine, alcohol, and nicotine may result in insomnia. Various diagnostic devices are used in sleep laboratories to diagnose this disorder.
  • Rising stress levels, the availability of patented molecules in the market, potential drugs in the clinical pipeline, the introduction of technologically advanced medical devices, and an aging population are all factors influencing the growth of the insomnia therapeutics market. As people become more aware of the effects of sleep deprivation on their daily lives, the adoption rate of various insomnia treatments is expected to rise, resulting in revenue growth for the insomnia therapeutics market.
  • The prevalence of insomnia is rising due to a number of other factors, including side effects from some over-the-counter and prescription medications, arthritis, and excessive use of media devices before bed, which is enhancing market growth prospects. The prevalence of psychological disorders and the escalating noise pollution in cities will also fuel the market for insomnia treatments during the forecast period. The growth of this market is also being fueled by emerging markets and significant R&D spending.

U.S. Insomnia

The U.S. Insomnia Market Trend Analysis

Growing Social Media Promotions and Celebrity Endorsements

The prevalence of different types of sleep disorders, such as insomnia and parasomnias, an increase in mental depression, and other painful conditions drives the growth of the insomnia market. Mental depression results in difficulty in sleep. For instance, the World Health Organization (WHO) reported that around 280 million population suffer from depression. Thus, the increase in mental depression across the population enhanced the market CAGR across the globe in recent years.

  • Long-term medication use for chronic disease treatment has some side effects that are thought to affect the patient's sleep quality. As a result, an increase in the prevalence of chronic diseases such as cancer drives market growth. According to the National Institute of Cancer (NIC), an estimated 1,806,590 new cancer cases will be diagnosed in the United States in 2020. Cancer chemotherapy has a variety of side effects on the patient's body, including a reduction in sleep quality, which is driving the growth of insomnia market revenue.
  • Furthermore, the rise in work-related stress contributes to the growth of the insomnia market. Workload increases and hectic work schedules result in poor sleep quality. Many people, such as security officers, work odd shifts, and the manufacturing industries are open 24 hours a day. These odd-time work shifts have an impact on sleep quality and cycle. An increase in the number of insomnia treatment centers and sleep diagnostic centers contributes to market growth. Insomnia treatment centers help people improve their sleep quality, while sleep diagnostic centers serve as diagnostic labs for detecting sleep disorders.
  • Increasing non-pharmacological sleep therapy adoption drives market growth. Insomnia is frequently linked to a person's mental health. As a result, non-pharmacological therapies like hypnotherapy, yoga, and cognitive behavioral therapy focus on improving a person's mental state and driving the insomnia industry.

Telemedicine and Virtual Sleep Clinics

  • The Insomnia Market in the United States is witnessing a notable opportunity through the emergence of telemedicine and virtual sleep clinics. Insomnia, a common sleep disorder affecting millions of Americans, has prompted a growing demand for convenient and accessible healthcare solutions. Telemedicine, enabled by advancements in technology and the widespread availability of high-speed internet, offers a promising avenue for addressing the healthcare needs of insomnia patients remotely. Telemedicine has revolutionized the way healthcare is delivered, providing a platform for patients to consult with healthcare professionals virtually. For individuals struggling with insomnia, the ability to access sleep experts and specialists from the comfort of their homes presents a game-changing opportunity. Through telemedicine platforms, patients can schedule video consultations, obtain personalized sleep assessments, and receive tailored treatment plans without the need for in-person visits to sleep clinics.
  • Moreover, telemedicine offers flexibility and convenience, especially for patients residing in remote or underserved areas, where access to specialized sleep clinics may be limited. By eliminating geographical barriers, telemedicine enables insomnia patients across the United States to connect with sleep experts regardless of their location, thereby widening access to quality healthcare services. Virtual sleep clinics are an extension of telemedicine, catering specifically to sleep disorders such as insomnia. These specialized online platforms are equipped with advanced technologies, including sleep tracking devices, to remotely monitor patients' sleep patterns and gather essential data for accurate diagnoses and treatment planning. Through virtual sleep clinics, insomnia patients can participate in sleep studies and receive real-time feedback from sleep specialists, enhancing the overall efficacy of treatment.

The rise in telemedicine adoption among adults in the United States has had a significant impact on the Insomnia Market. Telemedicine has transformed healthcare accessibility by allowing patients to receive medical consultations via virtual platforms, including for sleep-related issues such as insomnia. Because of the convenience and ease of access, more adults are seeking professional help for sleep problems.

Segmentation Analysis Of The U.S. Insomnia Market

U.S. Insomnia market segments cover the Therapy Type, Drug Class, and End-User. By Therapy Type, pharmacological therapy is Anticipated to Dominate the Market Over the Forecast period.

  • The pharmacological therapy segment dominated the market in 2020, and this trend is expected to continue throughout the forecast period, owing to an increase in the prevalence of insomnia and an increase in the number of key players producing therapeutic drugs for insomnia. However, the non-pharmacological therapy segment is expected to grow significantly during the forecast period, owing to increased demand for yoga and cognitive behavioral therapy, as well as advancements in healthcare technology.

COVID-19 Impact Analysis On U.S. Insomnia Market

The COVID-19 pandemic had a significant impact on the US insomnia market. As the pandemic changed daily routines, work patterns, and overall stress levels, it also caused an increase in sleep disturbances and insomnia cases across the country. The pandemic's uncertainty and anxiety increased sleeplessness, exacerbating existing sleep disorders and even causing new cases of insomnia.

The disruption of regular schedules and routines was one of the primary factors contributing to the increase in insomnia cases. Individuals faced challenges in separating work life from personal life as remote work became the norm for many, resulting in irregular sleep patterns and difficulties winding down at the end of the day. Furthermore, the isolation and social distancing measures used to control the virus's spread had a negative impact on mental health, causing increased stress, anxiety, and depression, all of which are known triggers for insomnia.

The impact of the pandemic on access to healthcare services also had an impact on the insomnia market. In many areas, non-urgent medical visits were postponed or canceled, causing delays in seeking treatment for sleep disorders. Furthermore, during the pandemic, the shift toward telemedicine presented both opportunities and challenges for the insomnia market.

Top Key Players Covered in The U.S. Insomnia Market

  • Eisai Co. Ltd. (Japan)
  • Merck & Co., Inc. (U.S.)
  • Meda Consumer Healthcare Inc. (U.S.)
  • Pfizer Inc. (U.S.)
  • Currax Pharmaceuticals LLC
  • Sanofi (France)
  • Takeda Pharmaceutical Company Ltd. (Japan)
  • Pernix Therapeutics (U.S.)
  • Vanda Pharmaceuticals, Inc.
  • Viatris, Inc.
  • Purdue Pharma L.P. (U.S.) and Other Major Players

Key Industry Developments in the U.S. Insomnia Market

In May 2022, Idorsia Ltd received marketing authorization from the European Commission for QUVIVIQ, which is indicated for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable impact on daytime functioning.

In January 2020, Idorsia received approval from the United States Food and Drug Administration for QUVIVIQ 25 and 50 mg for the treatment of adults with insomnia, characterized by difficulties with sleep onset and /or sleep maintenance.

U.S Insomnia Market

Base Year:

2022

Forecast Period:

2023-2030

Historical Data:

2017 to 2022

Market Size in 2022:

USD XXX Bn.

Forecast Period 2023-2030 CAGR:

XXX%

Market Size in 2030:

USD XXX Bn.

Segments Covered:

By Therapy Type

  • Non-Pharmacological Therapy
  • Pharmacological Therapy

By Drug Class

  • Antidepressants
  • Melatonin Antagonist
  • Benzodiazepines
  • Nonbenzodiazepines
  • Others

By End-User

  • Hospital
  • Homecare
  • Specialty Clinics
  • Others

Key Market Drivers:

  • Growing Social Media Promotions and Celebrity Endorsements

Key Market Restraints:

  • High Cost of Treatment

Key Opportunities:

  • Telemedicine and Virtual Sleep Clinics

Companies Covered in the report:

  • Eisai Co. Ltd. (Japan), Merck & Co., Inc. (U.S.), Meda Consumer Healthcare Inc. (U.S.), Pfizer Inc. (U.S.), Currax Pharmaceuticals LLC, and Other Major Players
  1. INTRODUCTION
    1. RESEARCH OBJECTIVES
    2. RESEARCH METHODOLOGY
    3. RESEARCH PROCESS
    4. SCOPE AND COVERAGE
      1. Market Definition
      2. Key Questions Answered
    5. MARKET SEGMENTATION
  2. EXECUTIVE SUMMARY
  3. MARKET OVERVIEW
  4. GROWTH OPPORTUNITIES BY SEGMENT
  5. MARKET LANDSCAPE
    1. PORTER’S FIVE FORCES ANALYSIS
      1. Bargaining Power Of Supplier
      2. Threat Of New Entrants
      3. Threat Of Substitutes
      4. Competitive Rivalry
      5. Bargaining Power Among Buyers
    2. INDUSTRY VALUE CHAIN ANALYSIS
    3. MARKET DYNAMICS
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
    4. MARKET TREND ANALYSIS
    5. REGULATORY LANDSCAPE
    6. PESTLE ANALYSIS
    7. PRICE TREND ANALYSIS
    8. PATENT ANALYSIS
    9. TECHNOLOGY EVALUATION
    10. ANALYSIS OF THE IMPACT OF COVID-19
      1. Impact On The Overall Market
      2. Impact On The Supply Chain
      3. Impact On The Key Manufacturers
      4. Impact On The Pricing
      5. Post COVID Situation
    11. MARKET IMPACT OF THE RUSSIA-UKRAINE WAR
      1. Geopolitical Market Disruptions
      2. Supply Chain Disruptions
      3. Instability in Emerging Markets
    12. ECOSYSTEM
  6. U.S. INSOMNIA MARKET BY THERAPY TYPE (2016-2030)
    1. U.S. INSOMNIA MARKET SNAPSHOT AND GROWTH ENGINE
    2. MARKET OVERVIEW
    3. NON-PHARMACOLOGICAL THERAPY
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2016 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2016 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
    4. PHARMACOLOGICAL THERAPY
  7. U.S. INSOMNIA MARKET BY DRUG CLASS  (2016-2030)
    1. U.S. INSOMNIA MARKET SNAPSHOT AND GROWTH ENGINE
    2. MARKET OVERVIEW
    3. ANTIDEPRESSANTS
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2016 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2016 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
    4. MELATONIN ANTAGONIST
    5. BENZODIAZEPINES
    6. NONBENZODIAZEPINES
    7. OTHERS
  8. U.S. INSOMNIA MARKET BY END-USER (2016-2030)
    1. U.S. INSOMNIA MARKET SNAPSHOT AND GROWTH ENGINE
    2. MARKET OVERVIEW
    3. HOSPITALS
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2016 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2016 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
    4. HOMECARE
    5. SPECIALTY CLINICS
    6. OTHERS
  9. COMPANY PROFILES AND COMPETITIVE ANALYSIS
    1. COMPETITIVE LANDSCAPE
      1. Competitive Positioning
      2. INSOMNIA Market Share By Manufacturer (2022)
      3. Industry BCG Matrix
      4. Heat Map Analysis
      5. Mergers & Acquisitions
    2. EISAI CO. LTD. (JAPAN)
      1. Company Overview
      2. Key Executives
      3. Company Snapshot
      4. Role of the Company in the Market
      5. Sustainability and Social Responsibility
      6. Operating Business Segments
      7. Product Portfolio
      8. Business Performance (Production Volume, Sales Volume, Sales Margin, Production Capacity, Capacity Utilization Rate)
      9. Key Strategic Moves And Recent Developments
      10. SWOT Analysis
    3. MERCK & CO. INC. (U.S.)
    4. MEDA CONSUMER HEALTHCARE INC. (U.S.)
    5. PFIZER INC. (U.S.)
    6. CURRAX PHARMACEUTICALS LLC
    7. SANOFI (FRANCE)
    8. TAKEDA PHARMACEUTICAL COMPANY LTD. (JAPAN)
    9. PERNIX THERAPEUTICS (U.S.)
    10. VANDA PHARMACEUTICALS, INC.
    11. VIATRIS INC.
    12. PURDUE PHARMA L.P. (U.S.)
    13. OTHER MAJOR PLAYERS
  10. INVESTMENT ANALYSIS
  11. ANALYST VIEWPOINT AND CONCLUSION
    1. Recommendations and Concluding Analysis
    2. Potential Market Strategies

U.S Insomnia Market

Base Year:

2022

Forecast Period:

2023-2030

Historical Data:

2017 to 2022

Market Size in 2022:

USD XXX Bn.

Forecast Period 2023-2030 CAGR:

XXX%

Market Size in 2030:

USD XXX Bn.

Segments Covered:

By Therapy Type

  • Non-Pharmacological Therapy
  • Pharmacological Therapy

By Drug Class

  • Antidepressants
  • Melatonin Antagonist
  • Benzodiazepines
  • Nonbenzodiazepines
  • Others

By End-User

  • Hospital
  • Homecare
  • Specialty Clinics
  • Others

Key Market Drivers:

  • Growing Social Media Promotions and Celebrity Endorsements

Key Market Restraints:

  • High Cost of Treatment

Key Opportunities:

  • Telemedicine and Virtual Sleep Clinics

Companies Covered in the report:

  • Eisai Co. Ltd. (Japan), Merck & Co., Inc. (U.S.), Meda Consumer Healthcare Inc. (U.S.), Pfizer Inc. (U.S.), Currax Pharmaceuticals LLC, and Other Major Players

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. US INSOMNIA MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. US INSOMNIA MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. US INSOMNIA MARKET COMPETITIVE RIVALRY
TABLE 005. US INSOMNIA MARKET THREAT OF NEW ENTRANTS
TABLE 006. US INSOMNIA MARKET THREAT OF SUBSTITUTES
TABLE 007. US INSOMNIA MARKET BY THERAPY TYPE
TABLE 008. NON-PHARMACOLOGICAL THERAPY MARKET OVERVIEW (2016-2030)
TABLE 009. PHARMACOLOGICAL THERAPY MARKET OVERVIEW (2016-2030)
TABLE 010. US INSOMNIA MARKET BY DRUG CLASS
TABLE 011. ANTIDEPRESSANTS MARKET OVERVIEW (2016-2030)
TABLE 012. MELATONIN ANTAGONIST MARKET OVERVIEW (2016-2030)
TABLE 013. BENZODIAZEPINES MARKET OVERVIEW (2016-2030)
TABLE 014. NONBENZODIAZEPINES MARKET OVERVIEW (2016-2030)
TABLE 015. OTHERS MARKET OVERVIEW (2016-2030)
TABLE 016. US INSOMNIA MARKET BY END-USER
TABLE 017. HOSPITALS MARKET OVERVIEW (2016-2030)
TABLE 018. HOMECARE MARKET OVERVIEW (2016-2030)
TABLE 019. SPECIALTY CLINICS MARKET OVERVIEW (2016-2030)
TABLE 020. OTHERS MARKET OVERVIEW (2016-2030)
TABLE 021. US INSOMNIA MARKET, BY THERAPY TYPE (2016-2030)
TABLE 022. US INSOMNIA MARKET, BY DRUG CLASS (2016-2030)
TABLE 023. US INSOMNIA MARKET, BY END-USER (2016-2030)
TABLE 024. US INSOMNIA MARKET, BY COUNTRY (2016-2030)
TABLE 025. EISAI CO. LTD. (JAPAN): SNAPSHOT
TABLE 026. EISAI CO. LTD. (JAPAN): BUSINESS PERFORMANCE
TABLE 027. EISAI CO. LTD. (JAPAN): PRODUCT PORTFOLIO
TABLE 028. EISAI CO. LTD. (JAPAN): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 028. MERCK & CO.: SNAPSHOT
TABLE 029. MERCK & CO.: BUSINESS PERFORMANCE
TABLE 030. MERCK & CO.: PRODUCT PORTFOLIO
TABLE 031. MERCK & CO.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 031. INC. (U.S.): SNAPSHOT
TABLE 032. INC. (U.S.): BUSINESS PERFORMANCE
TABLE 033. INC. (U.S.): PRODUCT PORTFOLIO
TABLE 034. INC. (U.S.): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 034. MEDA CONSUMER HEALTHCARE INC. (U.S.): SNAPSHOT
TABLE 035. MEDA CONSUMER HEALTHCARE INC. (U.S.): BUSINESS PERFORMANCE
TABLE 036. MEDA CONSUMER HEALTHCARE INC. (U.S.): PRODUCT PORTFOLIO
TABLE 037. MEDA CONSUMER HEALTHCARE INC. (U.S.): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 037. PFIZER INC. (U.S.): SNAPSHOT
TABLE 038. PFIZER INC. (U.S.): BUSINESS PERFORMANCE
TABLE 039. PFIZER INC. (U.S.): PRODUCT PORTFOLIO
TABLE 040. PFIZER INC. (U.S.): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 040. CURRAX PHARMACEUTICALS LLC: SNAPSHOT
TABLE 041. CURRAX PHARMACEUTICALS LLC: BUSINESS PERFORMANCE
TABLE 042. CURRAX PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
TABLE 043. CURRAX PHARMACEUTICALS LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 043. SANOFI (FRANCE): SNAPSHOT
TABLE 044. SANOFI (FRANCE): BUSINESS PERFORMANCE
TABLE 045. SANOFI (FRANCE): PRODUCT PORTFOLIO
TABLE 046. SANOFI (FRANCE): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 046. TAKEDA PHARMACEUTICAL COMPANY LTD. (JAPAN): SNAPSHOT
TABLE 047. TAKEDA PHARMACEUTICAL COMPANY LTD. (JAPAN): BUSINESS PERFORMANCE
TABLE 048. TAKEDA PHARMACEUTICAL COMPANY LTD. (JAPAN): PRODUCT PORTFOLIO
TABLE 049. TAKEDA PHARMACEUTICAL COMPANY LTD. (JAPAN): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 049. PERNIX THERAPEUTICS (U.S.): SNAPSHOT
TABLE 050. PERNIX THERAPEUTICS (U.S.): BUSINESS PERFORMANCE
TABLE 051. PERNIX THERAPEUTICS (U.S.): PRODUCT PORTFOLIO
TABLE 052. PERNIX THERAPEUTICS (U.S.): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 052. VANDA PHARMACEUTICALS: SNAPSHOT
TABLE 053. VANDA PHARMACEUTICALS: BUSINESS PERFORMANCE
TABLE 054. VANDA PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 055. VANDA PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 055. INC.: SNAPSHOT
TABLE 056. INC.: BUSINESS PERFORMANCE
TABLE 057. INC.: PRODUCT PORTFOLIO
TABLE 058. INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 058. VIATRIS: SNAPSHOT
TABLE 059. VIATRIS: BUSINESS PERFORMANCE
TABLE 060. VIATRIS: PRODUCT PORTFOLIO
TABLE 061. VIATRIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 061. INC.: SNAPSHOT
TABLE 062. INC.: BUSINESS PERFORMANCE
TABLE 063. INC.: PRODUCT PORTFOLIO
TABLE 064. INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 064. PURDUE PHARMA L.P. (U.S.): SNAPSHOT
TABLE 065. PURDUE PHARMA L.P. (U.S.): BUSINESS PERFORMANCE
TABLE 066. PURDUE PHARMA L.P. (U.S.): PRODUCT PORTFOLIO
TABLE 067. PURDUE PHARMA L.P. (U.S.): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 067. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 068. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 069. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 070. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. US INSOMNIA MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. US INSOMNIA MARKET OVERVIEW BY THERAPY TYPE
FIGURE 012. NON-PHARMACOLOGICAL THERAPY MARKET OVERVIEW (2016-2030)
FIGURE 013. PHARMACOLOGICAL THERAPY MARKET OVERVIEW (2016-2030)
FIGURE 014. US INSOMNIA MARKET OVERVIEW BY DRUG CLASS
FIGURE 015. ANTIDEPRESSANTS MARKET OVERVIEW (2016-2030)
FIGURE 016. MELATONIN ANTAGONIST MARKET OVERVIEW (2016-2030)
FIGURE 017. BENZODIAZEPINES MARKET OVERVIEW (2016-2030)
FIGURE 018. NONBENZODIAZEPINES MARKET OVERVIEW (2016-2030)
FIGURE 019. OTHERS MARKET OVERVIEW (2016-2030)
FIGURE 020. US INSOMNIA MARKET OVERVIEW BY END-USER
FIGURE 021. HOSPITALS MARKET OVERVIEW (2016-2030)
FIGURE 022. HOMECARE MARKET OVERVIEW (2016-2030)
FIGURE 023. SPECIALTY CLINICS MARKET OVERVIEW (2016-2030)
FIGURE 024. OTHERS MARKET OVERVIEW (2016-2030)
FIGURE 025. US INSOMNIA MARKET OVERVIEW BY COUNTRY (2016-2030)

Please Wait...

Frequently Asked Questions :

What would be the forecast period in the Insomnia Market research report?

The forecast period in the Insomnia Market research report is 2023-2030.

Who are the key players in the Insomnia Market?

Eisai Co. Ltd. (Japan), Merck & Co., Inc. (U.S.), Meda Consumer Healthcare Inc. (U.S.), Pfizer Inc. (U.S.), Currax Pharmaceuticals LLC, Sanofi (France), Takeda Pharmaceutical Company Ltd. (Japan), Pernix Therapeutics (U.S.), Vanda Pharmaceuticals, Inc., Viatris, Inc., Purdue Pharma L.P. (U.S.), and Other Major Players.

What are the segments of the Insomnia Market?

The Insomnia Market has been segmented into Therapy Type, Drug Class, End-User, and region. By Therapy Type, the market is categorized into Non-Pharmacological Therapy, Pharmacological Therapy. By Drug Class, the market is categorized into Antidepressants, Melatonin Antagonist, Benzodiazepines, Nonbenzodiazepines, Others. By End-Users, the market is categorized into Hospitals, Homecare, Specialty Clinics, Others.

What is the Insomnia Market?

Insomnia is a sleep disorder that makes it difficult to fall asleep or stay asleep. A person may also wake up too early and not be able to get back to sleep. Low stamina, daytime sleepiness, depression, and irritability are among the symptoms. It is a very common disorder that affects millions of people all over the world. Circadian rhythm disruption, chronic pain, hyperthyroidism, menopause, psychological stress, and other medical conditions all contribute to insomnia. Excessive use of drugs such as caffeine, alcohol, and nicotine may result in insomnia. Various diagnostic devices are used in sleep laboratories to diagnose this disorder.

How big is the Insomnia Market?

The Insomnia Market is expected to grow at a significant growth rate, and the analysis period is 2023-2030, considering the base year as 2022.